MoonLake Immunotherapeutics AG is a clinical-stage biotechnology company. It focused on creating next-level therapies for inflammatory skin and joint diseases. MoonLake Immunotherapeutics AG, formerly known as Helix Acquisition Corp., is based in BOSTON.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-118.94M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.04 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -30.81% |
| Return on Assets (Trailing 12 Months) | -28.40% |
| Current Ratio (Most Recent Fiscal Quarter) | 21.11 |
| Quick Ratio (Most Recent Fiscal Quarter) | 21.11 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.18 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $6.45 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.63 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.89 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.30 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 64.01M |
| Free Float | 56.32M |
| Market Capitalization | $2.49B |
| Average Volume (Last 20 Days) | 0.29M |
| Beta (Past 60 Months) | 1.31 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 12.02% |
| Percentage Held By Institutions (Latest 13F Reports) | 93.85% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |